|
|
|
Volumn 275, Issue 7373, 2005, Pages 546-
|
|
Branded prescribing of strong opioids should be adopted as good practice
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BUPRENORPHINE;
DILTIAZEM;
FENTANYL;
GENERIC DRUG;
MORPHINE SULFATE;
NARCOTIC ANALGESIC AGENT;
ACCURACY;
ANALGESIA;
BIOEQUIVALENCE;
COST EFFECTIVENESS ANALYSIS;
DOSE CALCULATION;
DRUG COST;
DRUG SAFETY;
GOOD CLINICAL PRACTICE;
HEALTH CARE COST;
HEALTH CARE PERSONNEL;
HUMAN;
MEDICATION ERROR;
MORTALITY;
NATIONAL HEALTH SERVICE;
NOTE;
PAIN;
PAIN ASSESSMENT;
PALLIATIVE THERAPY;
PHARMACEUTICAL CARE;
PHARMACIST;
PHARMACY;
PRACTICE GUIDELINE;
PRESCRIPTION;
PROFESSIONAL PRACTICE;
QUALITY OF LIFE;
RISK REDUCTION;
SIDE EFFECT;
SUSTAINED RELEASE FORMULATION;
TERMINALLY ILL PATIENT;
UNITED KINGDOM;
WELLBEING;
|
|
EID: 27844606856
PISSN: 00316873
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|